Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26	MAR 20	CAS databases on STN enhanced with new super role

```
                  for nanomaterial substances
 NEWS 27  MAR 23  CA/CAplus enhanced with more than 250,000 patent
                  equivalents from China
 NEWS 28  MAR 30  IMSPATENTS reloaded and enhanced
 NEWS 29  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:14:09 ON 06 APR 2009

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 08:14:19 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 APR 2009  HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES:   5 APR 2009  HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10551737 R5 aryl R6 and R8 ring.str
```

```
chain nodes :
7  12  13  14  17  19
ring nodes :
1  2  3  4  5  6  8  10  11  20
chain bonds :
4-17  5-7  7-8  10-11  11-12  12-13  12-14  17-19
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-20  10-20
exact/norm bonds :
4-17  5-7  7-8  8-20  10-11  10-20  12-13  12-14  17-19
exact bonds :
11-12
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6


G1:C,O,S

G2:O,S

G3:Cb,Cy,Hy

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  10:CLASS  11:CLASS
12:CLASS  13:CLASS  14:CLASS  17:CLASS  19:CLASS  20:CLASS



L1      STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1              STR
```



G1 C,O,S
G2 O,S
G3 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.70

FILE 'CAPLUS' ENTERED AT 08:14:35 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 08:14:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 41318 TO ITERATE

100.0% PROCESSED 41318 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L2 0 SEA SSS FUL L1

L3 0 L2

=> file marpat
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.50 187.58

FILE 'MARPAT' ENTERED AT 08:14:46 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 150 ISS 13 (20090403/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 20090048322 19 FEB 2009
DE 102007039155 19 FEB 2009
EP 2022798 11 FEB 2009
JP 2009035500 19 FEB 2009
WO 2009024087 26 FEB 2009
GB 2451715 11 FEB 2009
FR 2920023 20 FEB 2009
RU 2346937 20 FEB 2009
CA 2618420 24 JAN 2009

The new MARPAT User Guide is now available at:
http://www.cas.org/support/stngen/stndoc/marpat.html.

=> s L1 SSS full
FULL SEARCH INITIATED 08:14:50 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 80459 TO ITERATE

51.3% PROCESSED 41260 ITERATIONS 35 ANSWERS

89.5% PROCESSED 72011 ITERATIONS 78 ANSWERS

97.1% PROCESSED 78164 ITERATIONS 91 ANSWERS

99.2% PROCESSED 79809 ITERATIONS (1 INCOMPLETE) 96 ANSWERS

```
 99.8% PROCESSED    80307 ITERATIONS   (     1 INCOMPLETE)       96 ANSWERS

100.0% PROCESSED    80459 ITERATIONS   (     2 INCOMPLETE)       97 ANSWERS
SEARCH TIME: 00.01.33

L4            97 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   131.94     319.52

FILE 'CAPLUS' ENTERED AT 08:16:34 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 6 Apr 2009  VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009  (20090405/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l4
L5            97 L4

=> s L5 AND PY<=2003
      24034941 PY<=2003
L6            39 L5 AND PY<=2003

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 39 ANSWERS - CONTINUE? Y/(N):y

L6   ANSWER 1 OF 39  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2003:892617  CAPLUS  Full-text
DOCUMENT NUMBER:          139:358786
TITLE:                    Treatment of diabetes and diabetic complications with
                          sodium-hydrogen exchanger type 1 (NHE-1) inhibitors
INVENTOR(S):              Tracey, Wayne Ross; Treadway, Judith Lee
PATENT ASSIGNEE(S):       Pfizer Products Inc., USA
SOURCE:                   PCT Int. Appl., 73 pp.
                          CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092694	A1	20031113	WO 2003-IB1639	20030422 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2483927	A1	20031113	CA 2003-2483927	20030422 <--
AU 2003219421	A1	20031117	AU 2003-219421	20030422 <--
EP 1499317	A1	20050126	EP 2003-715232	20030422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009707	A	20050209	BR 2003-9707	20030422
MX 2004008646	A	20041206	MX 2004-8646	20040906
PRIORITY APPLN. INFO.:			US 2002-380028P P	20020502
			WO 2003-IB1639 W	20030422

OTHER SOURCE(S): MARPAT 139:358786

AB The invention provides methods for treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia-reperfusion injury, diabetic cardiac ischemia-reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. The invention also provides combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, the combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia-reperfusion injury, diabetic cardiac ischemia-reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:892447 CAPLUS Full-text
DOCUMENT NUMBER: 139:358784
TITLE: Treatment of diabetes and diabetic complications with NHE-1 inhibitors
INVENTOR(S): Tracey, W. Ross; Treadway, Judith L.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030212104	A1	20031113	US 2003-428521	20030501 <--

PRIORITY APPLN. INFO.: US 2002-380028P P 20020502
OTHER SOURCE(S): MARPAT 139:358784
AB This invention relates to methods of treating or preventing type 2 diabetes, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic microangiopathy, diabetic macroangiopathy, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury and/or insulin resistance syndrome (IRS) in mammals, particularly in humans, by administering a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor or a pharmaceutical composition containing such an inhibitor. This invention also relates to combinations comprising NHE-1 inhibitors and a second pharmaceutical agent, said combinations being useful in treating type 2 diabetes, IRS, diabetic neuropathy, diabetic cardiomyopathy, cataracts, diabetic retinopathy, foot ulcers, diabetic ischemia reperfusion injury, diabetic cardiac ischemia reperfusion injury, diabetic microangiopathy and/or diabetic macroangiopathy.

L6 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:796371 CAPLUS Full-text
DOCUMENT NUMBER: 139:307685
TITLE: Preparation of sulfonyl aryl or heteroaryl hydroxamic acid compounds as matrix metalloprotease inhibitors
INVENTOR(S): Bedell, Louis J.; Mcdonald, Joseph J.; Barta, Thomas E.; Becker, Daniel P.; Rao, Shashidhar N.; Freskos, John N.; Mischke, Brent V.; Getman, Daniel P.; Decrescenzo, Gary A.; Villamil, Clara I.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S. Pat. Appl. Publ., 200 pp., Cont.-in-part of U.S. Ser. No. 230,209.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030191317	A1	20031009	US 2000-728408	20001201 <--
US 6794511	B2	20040921		
WO 9838859	A1	19980911	WO 1998-US4300	19980304 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 20010020021	A1	20010906	US 1999-230209	19990624 <--
US 6380258	B2	20020430		
US 20030073845	A1	20030417	US 2001-909227	20010719 <--
US 6696449	B2	20040224		
US 20050075374	A1	20050407	US 2004-867391	20040614

PRIORITY APPLN. INFO.:

WO 1998-US4300	A1	19980304
US 1999-310813	B1	19990512
US 1999-230209	A2	19990624
US 1997-35182P	P	19970304
US 2000-569034	A2	20000511
US 2000-728408	A2	20001201

OTHER SOURCE(S): MARPAT 139:307685
GI



I

AB The title compds. [I; m, n = 0 or 1 and the sum of m + n is 0 or 1; the ring structure W is a 5- or 6-membered aromatic or heteroarom. ring; X = CH2 or (un)substituted NH2; R1 = (i) a substituent containing a 5- or 6-membered cyclohydrocarbyl, heterocyclyl, aryl or heteroaryl radical bonded directly to the depicted SO2 group or (ii) (un)substituted; R2, R3 = H, alkyl, alkenyl, alkynyl, hydroxyalkyl, O- or S-(un)substituted hydroxyalkyl or mercaptoalkyl, hydroxy, thiol, haloalkyl, N-(un)substituted amino, aminoalkyl, aminoalkanoylaminoalkyl, aminoalkoxy, or aminoalkoxyalkyl, heterocyclyl, heterocyclylalkyl, heterocyclyloxy, heterocyclylthio, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroarylthio; or CR2R3 together forms an (un)substituted 4- to 8-membered carbocyclic or heterocyclic ring, that is preferably a 5- or 6-membered ring; R5, R6 = H, alkyl, cycloalkyl, acylalkyl, halo, NO2, HO, cyano, alkoxy, haloalkyl, haloalkoxy, hydroxyalkyl, N-(un)substituted aminoalkyl or aminoalkoxy, thiol, alkylthio, arylthio, cycloalkylthio, cycloalkoxy, alkoxyalkoxy, perfluoroalkyl, haloalkyl, heterocyclyloxy; or R5 and R6 together with the atoms to which they are bonded form a further aliphatic or aromatic carbocyclic or heterocyclic ring having 5- to 7-members; R20 = each (un)substituted OH, NHOH, or NH2] or pharmaceutically acceptable salts thereof are prepared Also disclosed is a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroarom. ring hydroxamic acid compound in a matrix metalloprotease (MMP) enzyme-inhibiting effective amount to a host having a condition associated with pathol. MMP activity. Thus, thioetherification of 4-phenoxybenzenethiol with 2-fluorobenzaldehyde in the presence of K2CO3 in isopropanol under reflux for 20 h gave 2-(4-phenoxyphenylthio)benzaldehyde which was condensed with tetra-Et dimethylaminomethylenediphosphonate in the presence of NaH in THF at room temperature for 4 h gave to 2-[2-(4-phenoxyphenylthio)phenyl]acetic acid (II). II was oxidized by H2O2 in acetic acid to 2-[2-(4-phenoxyphenylsulfonyl)phenyl]acetic acid which was condensed with O-tetrahydropyranylhydroxylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in MeCN followed by treatment with p-toluenesulfonic acid in methanol at room temperature for 2 h to give N-hydroxy-2-[2-(4- phenoxyphenylsulfonyl)phenyl]acetamide (III). III and N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide showed IC50 of >10,000 nM against MMP-1, 0.3 and 2.4 nM, resp., against MMP-2, and 2 and 2.7 nM, resp., against MMP-13.

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:591152 CAPLUS Full-text

DOCUMENT NUMBER: 139:149539

TITLE: Preparation of 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor for use in pharmaceutical compositions for the treatment of central nervous system (CNS) disorders

INVENTOR(S): Ahmed, Mahmood; Bromidge, Steven Mark; Forbes, Ian Thomson; Gribble, Andrew Derrick; Johnson, Christopher

Norbert; King, Francis David; Lightfoot, Andrew P.;
Macdonald, Gregor James; Moss, Stephen Frederick;
Thompson, Mervyn; Witty, David R.
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062205	A1	20030731	WO 2002-EP14824	20021220 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1456178	A1	20040915	EP 2002-796752	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005518414	T	20050623	JP 2003-562087	20021220
US 20050176759	A1	20050811	US 2004-499776	20040621
PRIORITY APPLN. INFO.:			GB 2001-30702 A	20011221
			GB 2002-12398 A	20020529
			WO 2002-EP14824 W	20021220

OTHER SOURCE(S): MARPAT 139:149539
GI



I



II

AB Sulfonylbenzazepines, such as I [R = aryl, biaryl; R1 = H, alkyl; R2 = H, OH, CN, NO2 CF3, OCF3, alkyl, alkyoxy, alkanoyl, cycloalkyl, alkylsulfonyl, alkylthio, carbamoyl, sulfamoyl, etc.], were prepared for therapeutic use modulating dopamine receptors. These benzazepines are useful for the treatment or prophylaxis of CNS or psychotic disorders, such as depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, Parkinson's disease, substance abuse, dyskinetic disorders, bipolar disorder, sexual dysfunction, sleep disorders, emesis, movement disorders, obsessive-compulsive disorders, amnesia, aggression, autism, vertigo, dementia and circadian rhythm disorders. Thus benzazepine derivative II was prepared by reaction of 2,3,4,5-tetrahydro-3-(trifluoroacetyl)-1H-3- benzazepine-7-sulfonyl fluoride with 2-methyl-5-bromoaniline using t-BuLi in THF. The prepared benzazepines were tested for receptor binding activity for dopamine D2 and D3, 5-hydroxytryptamine 5-HT6,

5-HT2A, and 5-HT2C cloned human receptors and showed selectivity for the D2/D3 receptors.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:473266 CAPLUS Full-text

DOCUMENT NUMBER: 139:30862

TITLE: Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 464,344.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030114482	A1	20030619	US 2000-552823	20000420 <--
US 6313168	B1	20011106	US 1999-464344	19991215 <--
EP 1645271	A1	20060412	EP 2005-24409	20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
CA 2407021	A1	20011101	CA 2001-2407021	20010419 <--
WO 2001080894	A2	20011101	WO 2001-US12742	20010419 <--
WO 2001080894	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1274456	A2	20030115	EP 2001-928654	20010419 <--
EP 1274456	B1	20041229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531180	T	20031021	JP 2001-577990	20010419 <--
AT 285794	T	20050115	AT 2001-928654	20010419
AU 2001255488	B2	20060727	AU 2001-255488	20010419
HK 1053053	A1	20050610	HK 2003-105084	20030714
AU 2006233216	A1	20061116	AU 2006-233216	20061027

PRIORITY APPLN. INFO.:
US 1999-464344 A2 19991215
US 2000-552823 A 20000420
EP 2000-986336 A3 20001213
WO 2001-US12742 W 20010419

OTHER SOURCE(S): MARPAT 139:30862

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis or osteoporosis, comprising administering therapeutically effective amts. of retinoid receptor antagonists or retinoid receptor agonists.

L6 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:319918 CAPLUS Full-text
DOCUMENT NUMBER: 138:338216
TITLE: Preparation of pelorol derivatives as SHIP 1 modulators
INVENTOR(S): Andersen, Raymond; Williams, David E.; Mui, Alice; Ong, Christopher; Krystal, Gerald
PATENT ASSIGNEE(S): The University of British Columbia, Can.
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033517	A1	20030424	WO 2002-CA1550	20021017 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463136	A1	20030424	CA 2002-2463136	20021017 <--
AU 2002331507	A1	20030428	AU 2002-331507	20021017 <--
CA 2502293	A1	20040429	CA 2003-2502293	20030423
WO 2004035601	A1	20040429	WO 2003-CA571	20030423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003218843	A1	20040504	AU 2003-218843	20030423
EP 1554304	A1	20050720	EP 2003-714589	20030423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006506363	T	20060223	JP 2004-543854	20030423
US 20040266865	A1	20041230	US 2004-825858	20040416
US 20080090909	A1	20080417	US 2007-871086	20071011

PRIORITY APPLN. INFO.:		
US 2001-329506P	P	20011017
AU 2002-331507	A3	20021017
WO 2002-CA1550	W	20021017
WO 2003-CA571	W	20030423
US 2004-825858	A3	20040416

OTHER SOURCE(S): MARPAT 138:338216
GI



I

AB The present invention includes the use of pelorol and related sesquiterpene compds., e.g. of formula I [Y = CH2, CH2CH2; R1-R4 = H, OH, alkoxy, alkoxycarbonyl, CH2OH, etc.], as modulators of SHIP 1 activity. This invention also provides novel sesquiterpene compds. capable of modulating SHIP 1 activity and methods of synthesis thereof. No examples are given. The effect of pelorol on macrophage nitric oxide production is measured.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:282399 CAPLUS Full-text

DOCUMENT NUMBER: 138:304302

TITLE: Preparation of amidine-substituted polycyclic compound prodrugs useful for selective inhibition of serine proteases of the coagulation cascade

INVENTOR(S): South, Michael S.; Webber, Ronald K.; Huang, Horng-chih; Toth, Mihaly V.; Moormann, Alan E.; Snyder, Jeffrey S.; Scholten, Jeffrey A.; Garland, Danny J.; Rueppel, Melvin L.; Neumann, William L.; Long, Scott; Wei, Huang; Trujillo, John; Parlow, John J.; Jones, Darin E.; Case, Brenda; Hayes, Michael J.; Zeng, Qingping

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 547 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028729	A2	20030410	WO 2002-US31468	20021003 <--
WO 2003028729	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462601	A1	20030410	CA 2002-2462601	20021003 <--
AU 2002337805	A1	20030414	AU 2002-337805	20021003 <--
US 20030162776	A1	20030828	US 2002-263936	20021003 <--

```
    US 7105559          B2    20060912
    CA 2462645          A1    20031113    CA 2002-2462645         20021003 <--
    WO 2003093242       A2    20031113    WO 2002-US31770         20021003 <--
    WO 2003093242       A3    20040429
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
            UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
            CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    AU 2002367752       A1    20031117    AU 2002-367752          20021003 <--
    US 20040082585      A1    20040429    US 2002-263418          20021003
    EP 1432687          A2    20040630    EP 2002-807360          20021003
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
    BR 2002013129       A     20040810    BR 2002-13129           20021003
    BR 2002013099       A     20041019    BR 2002-13099           20021003
    EP 1482940          A2    20041208    EP 2002-773700          20021003
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
    JP 2005509606       T     20050414    JP 2003-532061          20021003
    JP 2005525413       T     20050825    JP 2004-501381          20021003
    MX 2004003169       A     20040708    MX 2004-3169            20040402
    MX 2004003170       A     20040708    MX 2004-3170            20040402
    US 20050239860      A1    20051027    US 2005-159684          20050623
    US 20050267123      A1    20051201    US 2005-159877          20050623
PRIORITY APPLN. INFO.:                      US 2001-326721P     P   20011003
                                            US 2001-338623P     P   20011024
                                            US 2001-332857P     P   20011106
                                            US 2001-344957P     P   20011107
                                            US 2001-350052P     P   20011107
                                            US 2001-333292P     P   20011114
                                            US 2001-331891P     P   20011121
                                            US 2001-332014P     P   20011121
                                            US 2001-332104P     P   20011121
                                            US 2001-332107P     P   20011121
                                            US 2002-263637      A1  20021003
                                            US 2002-263936      A1  20021003
                                            WO 2002-US31468     W   20021003
                                            WO 2002-US31770     W   20021003
OTHER SOURCE(S):            MARPAT 138:304302
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to prodrug compds., comprising a 5- or 6-membered heterocyclic or aromatic ring substituted with a derivatized amidine (shown as I and II; variables defined below; e.g. N-[4-[(Z)-amino[(pyridin-2-ylmethoxy)imino]methyl]benzyl]-2-[6-[3-amino-5- (trifluoromethyl)phenyl]-3-(isopropylamino)-2-oxopyrazin-1(2H)- yl]acetamide (shown as III)), as well as compns. and methods useful for preventing and treating thrombotic conditions in mammals. The prodrug compds. of the present invention selectively inhibit certain serine proteases of the coagulation cascade (no data). For I: X = 5-

or 6-membered heterocyclic or aromatic ring, the ring atoms being X1, X2, X3, X4, and X5 for 5-membered heterocyclic rings and X1, X2, X3, X4, X5 and X6 for 6-membered heterocyclic or aromatic rings, wherein X2 is alpha to each of X1 and X3, X3 is alpha to each of X2 and X4, X4 is alpha to each of X3 and X5, X5 is alpha to X4 and alpha to X1 if X is a 5-membered ring or to X6 if X is a 6-membered ring, and X6, when present, is alpha to each of X1 and X5, wherein X1, X2, X3, X4, X5 and X6 are C, N, O or S. L1, L3 and L4 are linkages through which Z1, Z3, and Z4, resp., are covalently bonded to different ring atoms of the 5- or 6-membered heterocyclic or aromatic ring of X, wherein Z1 is covalently bonded to X1, Z3 is covalently bonded to X3, and Z4 is covalently bonded to X4, each of L1, L3 and L4 independently being a covalent bond or comprising ≥1 atoms through which Z1, Z3, and Z4 are covalently bonded to X1, X3 and X4, resp. Z1 is hydrocarbyl or substituted hydrocarbyl; Z3 = 5- or 6-membered heterocyclic or aromatic ring substituted with a derivatized amidine which, upon hydrolysis, oxidation, reduction or elimination yields an amidine group, and optionally further substituted with a halogen or hydroxy, the ring atoms of the 5- or 6-membered heterocyclic or aromatic ring of Z3 being C, S, N, or O. Z4 = 5- or 6-membered heterocyclic or carbocyclic ring having two substituents, R42 and R44, and two ring atoms each of which is in the beta position relative to the ring atom of Z4 through which Z4 is covalently bonded to X, wherein one of R42 and R44 is covalently bonded to one of said beta positions and the other of R42 and R44 is covalently bonded to the other of said beta positions, the ring atoms of the 5- or 6-membered heterocyclic or carbocyclic ring of Z4 being C, N, O, or S. R42 is amino; and R44 = H, hydrocarbyl, substituted hydrocarbyl, heterocyclo, halogen, or a (un)substituted heteroatom = N, O, S and P; provided, however, the derivatized amidine is other than amidine derivatized with tert-butoxycarbonyl. For II: each of X1, X2, X3, X4, X5 and X6 is C or N; X2 is a H bond acceptor; X9 is a direct bond or -(CH2)m- where m is 1 to 5. The metabolic stability and/or bioavailability of .apprx.20 examples of I/II are tabulated. Although the methods of preparation are not claimed, .apprx.160 example prepns. are included.

L6 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:150646 CAPLUS Full-text
DOCUMENT NUMBER: 138:195820
TITLE: Rinse-processing composition for processing silver halide color photographic material, processing apparatus and processing method
INVENTOR(S): Seki, Hioyuki
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 55 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1286214	A1	20030226	EP 2002-18919	20020823 <--
EP 1286214	B1	20080312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20040043340	A1	20040304	US 2002-226180	20020823
US 7163783	B2	20070116		
PRIORITY APPLN. INFO.:			JP 2001-253095 A	20010823
			US 2002-226180 T	20020823
OTHER SOURCE(S):	MARPAT 138:195820			

AB A rinse-processing composition of the present invention comprises a compound represented by R-(OC2H4)n-OH, (R = C8-13 alkyl; n = 10-30), but comprises neither aldehyde compds. nor hexamethylenetetramine derivs. The present invention relates to a processing method and a processing apparatus using such a rinse-processing composition

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:129387 CAPLUS Full-text

DOCUMENT NUMBER: 138:164054

TITLE: Methods and compounds for the use of retinoic acid antagonists and inverse agonists as male anti-fertility agents

INVENTOR(S): Klein, Elliott S.; Yuan, Yang-Dar; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: U.S., 19 pp., Cont.-in-part of U.S. Ser. No. 405,748, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6521641	B1	20030218	US 2000-591253	20000609 <--
US 20030144256	A1	20030731	US 2002-304665	20021125 <--
US 20070054882	A1	20070308	US 2006-503635	20060814
PRIORITY APPLN. INFO.:			US 1998-103507P	P 19981008
			US 1999-405748	B2 19990927
			US 2000-591253	A1 20000609
			US 2002-304665	B1 20021125

OTHER SOURCE(S): MARPAT 138:164054

AB This continuation-in-part patent claims methods and compds. for the inhibition or prevention of spermatogenesis in a male mammal. The compds. claimed are antagonists or inverse agonists inhibiting the transcriptional activation of retinoic acid receptors RARα, RARβ and/or RARγ. Methods for the use of those compds. as anti-fertility agents to reduce or eliminate spermatozoa in the semen of male mammals to prevent conception are claimed.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:964331 CAPLUS Full-text

DOCUMENT NUMBER: 138:28938

TITLE: Dyeing composition for keratinous fibers comprising a particular dicationic diazo dye

INVENTOR(S): Vidal, Laurent; David, Herve

PATENT ASSIGNEE(S): L'oreal, Fr.

SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002100834	A1	20021219	WO 2002-FR1980	20020610 <--	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
FR 2825703	A1	20021213	FR 2001-7613	20010611 <--	
FR 2825703	B1	20080404			
AU 2002319365	A1	20021223	AU 2002-319365	20020610 <--	
EP 1399425	A1	20040324	EP 2002-748945	20020610	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2002010995	A	20040608	BR 2002-10995	20020610	
CN 1541207	A	20041027	CN 2002-815684	20020610	
CN 100429203	C	20081029			
JP 2005501134	T	20050113	JP 2003-503603	20020610	
MX 2003011339	A	20040319	MX 2003-11339	20031208	
US 20040244123	A1	20041209	US 2004-480202	20040728	
US 7001436	B2	20060221			
PRIORITY APPLN. INFO.:			FR 2001-7613	A 20010611	
			WO 2002-FR1980	W 20020610	

OTHER SOURCE(S): MARPAT 138:28938

AB The invention concerns a dyeing composition for dyeing keratinous fibers, in particular human keratinous fibers and more particularly hair, comprising a dicationic diazo dye as well as the dyeing method using same. Synthetic preparation of dicationic diazo dyes are described.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:868719 CAPLUS Full-text

DOCUMENT NUMBER: 137:346211

TITLE: Methods of treating hyperlipidemia by using retinoids as antagonists or inverse agonist of a retinoid receptor

INVENTOR(S): Yuan, Yang-Dar; Thacher, Scott M.; Klein, Elliot S.; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089781	A2	20021114	WO 2002-US13253	20020426 <--
WO 2002089781	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20020193403	A1	20021219	US 2001-848159	20010503	<--
CA 2445504	A1	20021114	CA 2002-2445504	20020426	<--
AU 2002259030	A1	20021118	AU 2002-259030	20020426	<--
EP 1392284	A2	20040303	EP 2002-729013	20020426	
EP 1392284	B1	20080827			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004532239	T	20041021	JP 2002-586918	20020426	
EP 1920771	A2	20080514	EP 2007-22682	20020426	
EP 1920771	A3	20080723			
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR					
AT 406159	T	20080915	AT 2002-729013	20020426	
US 20050171151	A1	20050804	US 2004-16534	20041217	
US 20080214652	A1	20080904	US 2008-72629	20080227	

PRIORITY APPLN. INFO.:	US 2001-848159	A	20010503
	EP 2002-729013	A3	20020426
	WO 2002-US13253	W	20020426
	US 2004-16534	B1	20041217

OTHER SOURCE(S): MARPAT 137:346211

AB The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a retinoid receptor to treat hyperlipidemia.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:849441 CAPLUS Full-text

DOCUMENT NUMBER: 137:353046

TITLE: Combinations of pyridazinone aldose reductase inhibitors and cyclooxygenase-2 inhibitors

INVENTOR(S): Mylari, Banavara Lakshman

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002087584	A1	20021107	WO 2002-IB643	20020225	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2445871	A1	20021107	CA 2002-2445871	20020225	<--
AU 2002236131	A1	20021111	AU 2002-236131	20020225	<--
AU 2002236131	B2	20050414			
HU 2003003920	A2	20040301	HU 2003-3920	20020225	

HU 2003003920	A3	20040728				
EP 1392310	A1	20040303	EP 2002-702611		20020225	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
CN 1505514	A	20040616	CN 2002-809037		20020225	
JP 2004528344	T	20040916	JP 2002-584929		20020225	
NZ 528150	A	20050324	NZ 2002-528150		20020225	
TW 228415	B	20050301	TW 2002-91104376		20020308	
US 20050004124	A1	20050106	US 2002-137472		20020430	
ZA 2003007204	A	20040915	ZA 2003-7204		20030915	
US 20040198740	A1	20041007	US 2004-810880		20040325	
PRIORITY APPLN. INFO.:			US 2001-287524P	P	20010430	
			WO 2002-IB643	W	20020225	
			US 2002-137472	A3	20020430	

OTHER SOURCE(S): MARPAT 137:353048

GI



I

AB Pharmaceutical compns. and kits comprise pyridazinones I [A = S, S(O), SO2; R1, R2 = H, Me; R3 = heterocyclic, heterocyclylalkyl, amino, CH2CH(OH)Ar, CH2COAr, arylamino, aralkyl; Ar = (un)substituted Ph, naphthyl] and cyclooxygenase-2 inhibitors for treatment or prevention of certain complications arising from diabetes mellitus and cardiac tissue ischemia in mammals (no data). Thus, 2-mercaptoindole was treated with 2-chloro-6-methoxypyridazine, followed by oxidation to the sulfone and demethylation to give 6-(indole-2-sulfonyl)-2H-pyridazin-3-one.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2002:793584 CAPLUS Full-text
DOCUMENT NUMBER:	137:310696
TITLE:	Preparation of N-hydroxyphenylacetamides as peptide deformylase inhibitors
INVENTOR(S):	Bhat, Ajita; Christensen, Siegfried B., IV; Frazee, James S.; Head, Martha S.; Leber, Jack Dale; Li, Mei
PATENT ASSIGNEE(S):	Smithkline Beecham Corporation, USA
SOURCE:	PCT Int. Appl., 22 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081426	A1	20021017	WO 2002-US10506	20020404 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002252585	A1	20021021	AU 2002-252585	20020404	<--
EP 1383729	A1	20040128	EP 2002-721667	20020404	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004527530	T	20040909	JP 2002-579414	20020404	
US 20040267015	A1	20041230	US 2003-473104	20030929	
PRIORITY APPLN. INFO.:			US 2001-281613P	P 20010405	
			WO 2002-US10506	W 20020404	

OTHER SOURCE(S): MARPAT 137:310696
GI



I

AB PDF inhibitors I [X = CO2(C1-6-alkyl), OR1, NR1R6, CONR1R6, C(:O)R6; R1 = H, (un)substituted C1-6-alkyl, Ar-(C1-6-alkyl); R1R6 = 5- or 6-membered cyclic system which may contain an O or (un)substituted N; R2 = I, Br, Cl, CHMe2, CMe3; R3 = H, I, Br, Cl,CHMe2, CMe3, ZR8; Z = O, N, NC(:O), C(:O)N, SO2N, CONHSO2, CH2; R6 = H, Me; R8 = (un)substituted C1-4-alkyl; Ar = (un)substituted Ph, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, tetrazolyl, imidazolyl, benzofuranyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrimidinyl] and novel methods for their use are provided. Thus, I (X = OC6H4OH, R2 = R3 = I) was prepared from 3,5-diiodothyroacetic acid via esterification with MeOH containing H2SO4 followed by amidation with NH2OH in aqueous dioxane. I was tested for PDF inhibition and antimicrobial activity (MIC = 0.06 - 64 mcg/mL).
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:755213 CAPLUS Full-text
DOCUMENT NUMBER: 137:279206
TITLE: Preparation of sulfenyl, sulfinyl and sulfonyl pyridazinone aldose reductase inhibitors for treating/preventing diabetic complications
INVENTOR(S): Mylari, Banavara L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20020143017	A1	20021003	US 2002-104664	20020321	<--
US 6579879	B2	20030617			
CA 2442476	A1	20021010	CA 2002-2442476	20020131	<--
WO 2002079198	A1	20021010	WO 2002-IB320	20020131	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002226634	A1	20021015	AU 2002-226634	20020131	<--
AU 2002226634	B2	20070125			
EP 1373259	A1	20040102	EP 2002-716247	20020131	
EP 1373259	B1	20041229			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EE 200300470	A	20040216	EE 2003-470	20020131	
HU 2003003644	A2	20040301	HU 2003-3644	20020131	
HU 2003003644	A3	20080630			
BR 2002008571	A	20040323	BR 2002-8571	20020131	
NZ 528406	A	20040326	NZ 2002-528406	20020131	
CN 1500087	A	20040526	CN 2002-807600	20020131	
CN 1215067	C	20050817			
JP 2004528319	T	20040916	JP 2002-577823	20020131	
EP 1491540	A1	20041229	EP 2004-23149	20020131	
EP 1491540	B1	20061213			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EP 1491541	A1	20041229	EP 2004-23150	20020131	
EP 1491541	B1	20070124			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
AT 286049	T	20050115	AT 2002-716247	20020131	
PT 1373259	T	20050331	PT 2002-716247	20020131	
ES 2231681	T3	20050516	ES 2002-716247	20020131	
DE 60202452	C5	20061123	DE 2002-60202452	20020131	
AT 348100	T	20070115	AT 2004-23149	20020131	
AT 352551	T	20070215	AT 2004-23150	20020131	
ES 2274369	T3	20070516	ES 2004-23149	20020131	
TW 245762	B	20051221	TW 2002-91106386	20020329	
US 20030162784	A1	20030828	US 2003-370895	20030220	<--
US 6849629	B2	20050201			
ZA 2003004671	A	20040625	ZA 2003-4671	20030617	
IN 2003MN00639	A	20050318	IN 2003-MN639	20030624	
BG 108179	A	20040930	BG 2003-108179	20030917	
NO 2003004345	A	20030929	NO 2003-4345	20030929	<--
MX 2003008850	A	20031204	MX 2003-8850	20030929	<--
HK 1061678	A1	20051104	HK 2004-104538	20040624	
US 20050113381	A1	20050526	US 2004-968759	20041018	

PRIORITY APPLN. INFO.:			
	US 2001-280051P	P	20010330
	EP 2002-716247	A3	20020131
	WO 2002-IB320	W	20020131

US 2002-104664 A3 20020321
US 2003-370895 A3 20030220

OTHER SOURCE(S): MARPAT 137:279206
GI

I

AB The present invention relates to novel pyridazinone compds. (shown as I; variables partially described below; e.g. 6-(2-indolylsulfonyl)-2H-pyridazin-3-one), pharmaceutical compns. comprising those compds. and to methods of using such compds. and compns. to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compns. and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compns. or kits to treat or prevent the above diabetic complications in mammals. This invention also relates to other combinations with the ARIs of this invention, including combinations with adenosine agonists; NHE-1 inhibitors; glycogen phosphorylase inhibitors; selective serotonin reuptake inhibitors; GABA agonists; antihypertensive agents; 3-hydroxy-3-methylglutaryl CoA reductase inhibitors; phosphodiesterase-5 inhibitors; and to glucose lowering agents. In I, A is S, SO or SO2; R1 and R2 are each independently H or Me; R3 is heteroaryl, -CHR4(heteroaryl) or NR6R7; R4 is H or (C1-C3)alkyl; R6 is (C1-C6)alkyl, aryl or heteroaryl; R7 is heteroaryl. No pharmacol. data is included. Although the methods of preparation are not claimed, .apprx.50 example prepns. are included.

L6 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:798081 CAPLUS Full-text
DOCUMENT NUMBER: 135:339297
TITLE: Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080894	A2	20011101	WO 2001-US12742	20010419 <--
WO 2001080894	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 20030114482	A1	20030619	US 2000-552823	20000420	<--
CA 2407021	A1	20011101	CA 2001-2407021	20010419	<--
EP 1274456	A2	20030115	EP 2001-928654	20010419	<--
EP 1274456	B1	20041229			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003531180	T	20031021	JP 2001-577990	20010419	<--
AT 285794	T	20050115	AT 2001-928654	20010419	
AU 2001255488	B2	20060727	AU 2001-255488	20010419	
HK 1053053	A1	20050610	HK 2003-105084	20030714	
AU 2006233216	A1	20061116	AU 2006-233216	20061027	
PRIORITY APPLN. INFO.:			US 2000-552823	A 20000420	
			US 1999-464344	A2 19991215	
			WO 2001-US12742	W 20010419	

OTHER SOURCE(S): MARPAT 135:339297

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis or osteoporosis, comprising administering therapeutically effective amts. of retinoid receptor antagonists or retinoid receptor agonists.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:693315 CAPLUS Full-text
DOCUMENT NUMBER: 135:242245
TITLE: Preparation of 6-aminoalkyl-2-heterocyclyl-4-phenyldihydropyrimidine-5-carboxylates as antiviral agents for treatment of hepatitis B infection.
INVENTOR(S): Goldmann, Siegfried; Stoltefuss, Juergen; Niewoehner, Ulrich; Schlemmer, Karl-Heinz; Keldenich, Joerg; Paessens, Arnold; Graef, Erwin; Weber, Olaf; Deres, Karl
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2001068641	A1	20010920	WO 2001-EP2443	20010305	<--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
DE 10013126 A1 20010920 DE 2000-10013126 20000317 <--
PRIORITY APPLN. INFO.: DE 2000-10013126 A 20000317
OTHER SOURCE(S): MARPAT 135:242245
GI



I



II

AB Title compds. I and II [R1 = (substituted) pyridyl, pyrimidyl, pyrazinyl, thiazolyl; R2 = (substituted) aryl, heteroaryl; R3 = (substituted) (O-, S-interrupted) alkyl; R4 = (substituted) alkyl, aryl, heteroaryl, etc.; R5 = H, (substituted) (interrupted) alkyl, heteroaryl, etc.; R4R5 = (substituted) (interrupted) cycloalkyl, etc.; X = (substituted) (O-interrupted) alkylene], were prepared Thus, Me (R)-6-bromomethyl-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)- 1,4-dihydropyrimidine-5-carboxylate (preparation given) was stirred with Na2CO3 and 1-cyclopropylpiperazine dihydrochloride in MeOH for 2 h at room temperature to give 87.6% Me (R)-4-(2-chloro-4-fluorophenyl)-6-[(4-cyclopropyl-1- piperazinyl)methyl]-2-(2,3-difluoro-2-pyridinyl)-1,4-dihydropyrimidine-5- carboxylate. Several title compds. inhibited intra- or extracellular DNA of hepatitis B virus-producing Hep G2.2.15-cells with inhibited with IC50 = 0.015-0.08 μM.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:472731 CAPLUS Full-text
DOCUMENT NUMBER: 135:61439
TITLE: Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
INVENTOR(S): Leblanc, Yves; Dufresne, Claude; Gauthier, Jacques Yves; Lau, Cheuk Kun; Li, Chun Sing; Roy, Patrick; Therien, Michel; Scheigetz, John; Wang, Zhaoyin
PATENT ASSIGNEE(S): Merck Frosst Canada & Co., Can.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046206	A1	20010628	WO 2000-CA1550	20001221 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2393367	A1	20010628	CA 2000-2393367		20001221 <--
US 20020058644	A1	20020516	US 2000-745211		20001221 <--
US 6486142	B2	20021126			
EP 1244678	A1	20021002	EP 2000-986935		20001221 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003518130	T	20030603	JP 2001-547115		20001221 <--
PRIORITY APPLN. INFO.:			US 1999-171520P	P	19991222
			WO 2000-CA1550	W	20001221

OTHER SOURCE(S): MARPAT 135:61439

AB Twenty-four antidiabetic and antiobesity title compds. were prepared by standard methods. Among the compds. prepared were: 2-bromo-4-[2-phenyl-2-(5-phenyl-1,2,4-oxadiazol-3- yl)ethyl]phenyl(difluoro)methylphosphonic acid and [(isopropoxycarbonyl)oxy]methyl hydrogen [2-bromo-4-(3-oxo-2,3-diphenyl)phenyl](difluoro)methyl phosphate. The invention also encompasses pharmaceutical compns. and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and conditions related to diabetes.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2001:452848 CAPLUS Full-text
DOCUMENT NUMBER: 135:41045
TITLE: Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
INVENTOR(S): Pacifici, Maurizio; Chandraratna, Roshantha A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001043732	A2	20010621	WO 2000-US33697		20001213 <--
WO 2001043732	A3	20020321			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6313168	B1	20011106	US 1999-464344		19991215 <--
CA 2394210	A1	20010621	CA 2000-2394210		20001213 <--
EP 1248602	A2	20021016	EP 2000-986336		20001213 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2003519103	T	20030617	JP 2001-544671		20001213 <--
AU 784189	B2	20060216	AU 2001-22593		20001213
EP 1645271	A1	20060412	EP 2005-24409		20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					

PRIORITY APPLN. INFO.: US 1999-464344 A 19991215
EP 2000-986336 A3 20001213
WO 2000-US33697 W 20001213

OTHER SOURCE(S): MARPAT 135:41045

AB The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis, comprising administering therapeutically effective amts. of retinoid receptor antagonists. AG1-X2 ion exchange beads were soaked for 1 h in a solution of 4-[[5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2- naphthalenyl]ethynyl]-benzoic acid (AGN 109) and implanted in the vicinity of the prospective humeral mesenchymal condensation in stage 21-22 chick embryos and determined whether humerus development had been impaired by day 10 in vivo. AGN 109-containing beads showed striking effects on humerus development.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:396864 CAPLUS Full-text
DOCUMENT NUMBER: 135:19632
TITLE: Preparation of pyrazolyl- and pyrrolylalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
INVENTOR(S): Momose, Yu; Maekawa, Tsuyoshi; Odaka, Hiroyuki; Kimura, Hiroyuki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 375 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001038325	A1	20010531	WO 2000-JP7877	20001109 <--
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2390923	A1	20010531	CA 2000-2390923	20001109 <--
JP 2001226350	A	20010821	JP 2000-347462	20001109 <--
JP 3723071	B2	20051207		
BR 2000015466	A	20020806	BR 2000-15466	20001109 <--
EP 1228067	A1	20020807	EP 2000-974857	20001109 <--
EP 1228067	B1	20040714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002003165	A2	20030128	HU 2002-3165	20001109 <--
HU 2002003165	A3	20040329		
JP 2003137865	A	20030514	JP 2002-315096	20001109 <--
NZ 519238	A	20031128	NZ 2000-519238	20001109 <--
AT 271049	T	20040715	AT 2000-974857	20001109
EP 1457490	A1	20040915	EP 2004-76508	20001109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PT 1228067	T	20041130	PT 2000-974857	20001109
ES 2225252	T3	20050316	ES 2000-974857	20001109

AU 780948	B2	20050428	AU 2001-13031		20001109	
RU 2252939	C2	20050527	RU 2002-115263		20001109	
CN 1260227	C	20060621	CN 2000-817467		20001109	
NO 2002002108	A	20020708	NO 2002-2108		20020502	<--
MX 2002004647	A	20021031	MX 2002-4647		20020509	<--
US 7179823	B1	20070220	US 2002-129702		20020509	
IN 2002KN00645	A	20050311	IN 2002-KN645		20020513	
ZA 2002003824	A	20031015	ZA 2002-3824		20020514	<--
HK 1045991	A1	20041210	HK 2002-106297		20020827	
PRIORITY APPLN. INFO.:			JP 1999-320317	A	19991110	
			JP 1999-352237	A	19991210	
			JP 1999-352236	A	19991210	
			EP 2000-974857	A3	20001109	
			JP 2000-347462	A3	20001109	
			WO 2000-JP7877	W	20001109	

OTHER SOURCE(S): MARPAT 135:19632

GI



I



II

AB Title compds. (I) [wherein R1 = (un)substituted hydrocarbon or heterocycle; X = bond, O, S, CO, CS, CR4(OR5), or NR6; R4 and R6 = independently H or (un)substituted hydrocarbon; R5 = H or hydroxyl protective group; m = 0-3; Y = O, S, SO, SO2, NR7, CONR7, or NR7CO; R7 = H or (un)substituted hydrocarbon; A = (un)substituted aromatic ring; n = 1-8; B = (un)substituted N-containing 5-membered heterocycle; X1 = bond, O, S, SO, SO2, OSO2, or NR16; R16 = H or (un)substituted hydrocarbon; R2 = H or (un)substituted hydrocarbon or heterocycle; W = bond or hydrocarbon; R3 = OR8 or NR9R10; R8 = H or (un)substituted hydrocarbon; R9 and R10 = independently H or (un)substituted hydrocarbon or heterocycle; or R9 and R10 together with the N to which they are attached may form a ring] were prepared as retinoid-related receptor function regulating agents or insulin resistance improving agents. For example, Et 3-[1-(4-hydroxybenzyl)-4-phenyl-3-pyrrolyl]propionate and 4-chloromethyl-5-methyl-2-(2-thienyl)oxazole were coupled in the presence of K2CO3 in DMF and treated with HCl to give II (77%). At a concentration of 0.001%, II reduced hypoglycemic and hypolipidemic action by 48% and 70%, resp., lowered total cholesterol by 16%, and increased the plasma anti-arteriosclerosis index by 12% compared to non-treatment groups of mice. In addition, II showed potent PPARγ-RXRα heterodimer ligand activity with EC50 of 1.5 nM. I are useful for the prevention or treatment of diabetes mellitus, hyperlipidemia, impaired glucose tolerance, inflammatory diseases, and arteriosclerosis.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 20 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:247339 CAPLUS Full-text
DOCUMENT NUMBER: 134:261280
TITLE: Azepinoindolone derivatives as poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Lubisch, Wilfried; Kock, Michael; Hoeger, Thomas; Grandel, Roland; Mueller, Reinhold; Schult, Sabine
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023390	A2	20010405	WO 2000-EP9024	20000915 <--
WO 2001023390	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19946289	A1	20010329	DE 1999-19946289	19990928 <--
DE 10039610	A1	20020228	DE 2000-10039610	20000809 <--
CA 2352194	A1	20010405	CA 2000-2352194	20000915 <--
BR 2000007174	A	20010904	BR 2000-7174	20000915 <--
EP 1183259	A2	20020306	EP 2000-974379	20000915 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001004917	A2	20020429	HU 2001-4917	20000915 <--
HU 2001004917	A3	20021228		
JP 2003510328	T	20030318	JP 2001-526542	20000915 <--
MX 2001005199	A	20020311	MX 2001-5199	20010524 <--
NO 2001002567	A	20010625	NO 2001-2567	20010525 <--
IN 2001CN00726	A	20050304	IN 2001-CN726	20010525
BG 105650	A	20020228	BG 2001-105650	20010626 <--
PRIORITY APPLN. INFO.:			DE 1999-19946289 A	19990928
			DE 2000-10039610 A	20000809
			WO 2000-EP9024 W	20000915

OTHER SOURCE(S): MARPAT 134:261280
AB Enantiomeric and diastereomeric forms and prodrugs of azepinoindolone derivs. such as 2-(4-(4-n-propylpiperazin-1-yl)phenyl)-1,3,4,5-tetrahydro- 6H-azepino[5,4,3-c,d]indol-6-one are useful as poly(ADP-ribose) polymerase inhibitors. The effectiveness of the title compds. in inhibiting poly(ADP-ribose) polymerase was demonstrated.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:185763 CAPLUS Full-text
DOCUMENT NUMBER: 134:207967
TITLE: Preparation of electronically tuned ligands

INVENTOR(S): Busacca, Carl
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018012	A1	20010315	WO 2000-US24162	20000905 <--
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2382163	A1	20010315	CA 2000-2382163	20000905 <--
US 6316620	B1	20011113	US 2000-655115	20000905 <--
EP 1218388	A1	20020703	EP 2000-959804	20000905 <--
EP 1218388	B1	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003508538	T	20030304	JP 2001-522235	20000905 <--
AT 258556	T	20040215	AT 2000-959804	20000905
PT 1218388	T	20040531	PT 2000-959804	20000905
ES 2213600	T3	20040901	ES 2000-959804	20000905
MX 2002002353	A	20020730	MX 2002-2353	20020304 <--

PRIORITY APPLN. INFO.: US 1999-152909P P 19990908
WO 2000-US24162 W 20000905

OTHER SOURCE(S): MARPAT 134:207967
GI



I

AB The preparation of phosphino- or arsinoamidines I (M = P, As; X, Y, Z = independently selected from H, alkyl, aryl (pendant or fused), halo, C1-10 alkoxy, cyano, nitro, amino, alkylamino, dialkylamino, CO2H, -CO(lower alkoxy), -CO(lower alkyl), -NCOH, -NCO(lower alkyl), NSO2(alkyl), -NSO2(aryl), hydroxy, alkyl, sulfonoxyalkyl, sulfonoxyaryl, alkoxyalkyl; R1 = H, C1-10 alkyl, branched alkyl or cycloalkyl; aryl, substituted aryl, heteroaryl or substituted heteroaryl where the heteroatoms are N, O, S, acyl, aroyl, substituted aroyl, heteroaroyl, substituted heteroaroyl, or SO2R4; R4 = alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl groups in direct attachment, with the provisos that R2 and R3 can be the same or different and are H, aryl, heteroaryl as defined above, substituted aryl or

heteroaryl as defined (with substituents as defined below), alkyl, branched alkyl, cycloalkyl, benzyl, substituted benzyl, with substituents as defined for aryl, or R2 and R3 together may form a fused carbocyclic ring, Ring B is an imidazoline ring or a tetrahydropyrimidine ring), useful as cocatalyst for stereoselective synthesis, is described. Thus, preparation of title ligand cocatalyst 2-(2'-diphenylphosphinophenyl)-3-(2''-naphthoyl)-(4S,5S)-diphenyl-4,5- dihydroimidazole, is described in four steps starting from 2-FC6H4CONH2; the use of prepared ligand as cocatalyst for asym. Heck reaction is also described.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:78220 CAPLUS Full-text
DOCUMENT NUMBER: 134:125939
TITLE: The use of retinoid receptor antagonists in the treatment of prostate carcinoma
INVENTOR(S): Chandraratna, Roshantha A.; Brown, Geoffrey
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007028	A2	20010201	WO 2000-US19849	20000721 <--
WO 2001007028	A3	20010830		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-145287P P 19990723
OTHER SOURCE(S): MARPAT 134:125939
AB Methods for treating prostate cancer comprise administering a therapeutically effective amount of a retinoid receptor antagonist. In addition, the invention provides methods of inhibiting the growth of a prostate carcinoma cell or tumor, the method comprising contacting the cell or tumor with an effective amount of a retinoid receptor antagonist.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:63991 CAPLUS Full-text
DOCUMENT NUMBER: 134:115959
TITLE: Preparation of novel 4,4-diphenylpiperidines for the treatment of chemokine receptor related diseases and conditions
INVENTOR(S): Baxter, Andrew John Gilby; Brough, Stephen John; McInally, Thomas
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20010005782	A1	20010125	WO 2000-GB2756	20000718 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2378084	A1	20010125	CA 2000-2378084	20000718 <--
BR 2000012610	A	20020409	BR 2000-12610	20000718 <--
EP 1202984	A1	20020508	EP 2000-946134	20000718 <--
EP 1202984	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505383	T	20030212	JP 2001-511441	20000718 <--
AT 233754	T	20030315	AT 2000-946134	20000718 <--
NZ 516606	A	20030926	NZ 2000-516606	20000718 <--
AU 771344	B2	20040318	AU 2000-60016	20000718
CN 1152873	C	20040609	CN 2000-810670	20000718
US 6566376	B1	20030520	US 2000-623744	20000908 <--
ZA 2001010540	A	20030324	ZA 2001-10540	20011221 <--
NO 2002000282	A	20020321	NO 2002-282	20020118 <--
MX 2002000671	A	20020702	MX 2002-671	20020118 <--

PRIORITY APPLN. INFO.: SE 1999-2765 A 19990721
WO 2000-GB2756 W 20000718

OTHER SOURCE(S): MARPAT 134:115959
GI



I



II

AB The title compds. [I; R1, R2 = (un)substituted Ph; R3 = halo, NO2, alkyl, etc.; n = 0-3; R4 = H, OH, NR10R11; A = CO, CH2, a bond; Q = alkylene; U, W and X = (un)substituted C, N; V = (un)substituted N, O; Y = alkylene, CO; R10,

R11 = H, alkyl, unsatd. alkyl, etc.; NR10R11 = (un)substituted 4-8 membered saturated azacyclic ring] and their pharmaceutically acceptable salts, useful in therapy, especially for the treatment of chemokine receptor related diseases and conditions (no data), were prepared E.g., a 2-step synthesis of 4,4-diphenylpiperidine II was given.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:686089 CAPLUS Full-text

DOCUMENT NUMBER: 133:268546

TITLE: Group VIII metal complexes with phosphinamidite ligands as catalysts for hydroformylation or hydrocyanation of olefins

INVENTOR(S): Ahlers, Wolfgang; Maas, Heiko; Roeper, Michael

PATENT ASSIGNEE(S): BASF A.-G., Germany

SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19913352	A1	20000928	DE 1999-19913352	19990324 <--
WO 2000056451	A1	20000928	WO 2000-EP2610	20000323 <--
W: CN, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1163051	A1	20011219	EP 2000-918832	20000323 <--
EP 1163051	B1	20041110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002539920	T	20021126	JP 2000-606345	20000323 <--
US 6852661	B1	20050208	US 2001-937310	20010924

PRIORITY APPLN. INFO.: DE 1999-19913352 A 19990324
WO 2000-EP2610 W 20000323

OTHER SOURCE(S): MARPAT 133:268546

GI



I

AB Group VIII metal complexes with mono- or multidentate phosphinamidite ligands of specified structure are used as catalysts for hydroformylation or hydrocyanation of olefins, e.g., 1-octene or 3-pentenenitrile. For example, chlorination of biphenyl-2-ol with PCl3 in the presence of ZnCl2 gave 69% 6-chloro-(6H)-dibenz[c,e][1,2]oxaphosphorin. Stirring of the latter with K-metalated pyrrole for 12 h at ambient temperature in THF gave 50% of a title

ligand I. Hydroformylation of 22.5 g 1-octene with synthesis gas (CO/H = 1:1; 40 bar) in the presence of 123 mg (acac)Rh(CO)2 (acacH = acetylacetone) and 680 mg I gave nonanal isomers with 96% selectivity.

L6 ANSWER 25 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:441769 CAPLUS Full-text
DOCUMENT NUMBER: 133:73851
TITLE: Preparation of novel herbicidally active benzoyl derivatives
INVENTOR(S): Schaetzer, Juergen; De Mesmaeker, Alain; Lee, Shy-Fuh
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037437	A1	20000629	WO 1999-EP10128	19991220 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9916396	A	20010911	BR 1999-16396	19991220 <--
EP 1140811	A1	20011010	EP 1999-963584	19991220 <--
EP 1140811	B1	20060802		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
AT 334961	T	20060815	AT 1999-963584	19991220
CN 100386313	C	20080507	CN 1999-814885	19991220
US 20020165096	A1	20021107	US 2001-886896	20010621 <--
US 6599861	B2	20030729		
US 20030236167	A1	20031225	US 2003-454966	20030605 <--
US 7265230	B2	20070904		
US 20070265165	A1	20071115	US 2007-828598	20070726

PRIORITY APPLN. INFO.:

CH 1998-2521	A	19981221
WO 1999-EP10128	W	19991220
US 2001-886896	A3	20010621
US 2003-454966	A3	20030605

OTHER SOURCE(S): MARPAT 133:73851
GI



I

AB The title compds. [I; X = CH2OMe, CH2OEt, CH2OH, etc.; R1, R2 = halo, CN, NO2, etc.; R3 = H, alkyl, halo; Q = 5,6-dihydro-5-hydroxy-3-oxo-2,6,6-trimethyl-2H-[1,2]oxazin-4-yl, 4-hydroxy-2-oxo-bicyclo[3.2.1]oct-3-en-3-yl, etc.] which are eminently suitable for use as herbicides, were prepared E.g., a 2-step synthesis of I [X = CH2OMe; R1 = Me; R2 = SO2Me; R3 = H; Q = 5,6-dihydro-5-hydroxy-3-oxo-2,6,6-trimethyl-2H-[1,2]oxazin-4-yl] which showed good herbicidal action against Setaria and Cyperus in pre-emergent and post-emergent action tests at 2000 g AS/ha, was given.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:240931 CAPLUS Full-text

DOCUMENT NUMBER: 132:274821

TITLE: Male antifertility agents

INVENTOR(S): Klein, Elliott S.; Yuan, Yang-Dar; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2000019990	A2	20000413	WO 1999-US22222	19990924	<--
WO 2000019990	A3	20000720			
W: AU, CA, JP					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2346687	A1	20000413	CA 1999-2346687	19990924	<--
AU 9961623	A	20000426	AU 1999-61623	19990924	<--
AU 757448	B2	20030220			
EP 1119350	A2	20010801	EP 1999-948451	19990924	<--
EP 1119350	B1	20050223			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2002526405	T	20020820	JP 2000-573351	19990924	<--
AT 289507	T	20050315	AT 1999-948451	19990924	
PRIORITY APPLN. INFO.:			US 1998-103507P	P 19981008	
			WO 1999-US22222	W 19990924	

OTHER SOURCE(S): MARPAT 132:274821

GI



I

AB Methods and compns. for inhibiting or preventing spermatogenesis in a male mammal are disclosed. AGN 194310 (I) was prepared and orally administered to rats and was not toxic and expts. showed that daily oral delivery of this RAR antagonist was sufficient to cause spermatogenic arrest.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:84792 CAPLUS Full-text

DOCUMENT NUMBER: 132:122612

TITLE: Preparation of benzoxazole derivatives for inhibiting the interaction between VCAM-1 and/or fibronectin and the integrin receptor VLA-4

INVENTOR(S): Brittain, David Robert; Johnstone, Craig; Davies, Gareth Morse; Large, Michael Stewart

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000005224	A2	20000203	WO 1999-GB2342	19990720 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9950530	A	20000214	AU 1999-50530	19990720 <--
EP 1144393	A2	20011017	EP 1999-934897	19990720 <--
EP 1144393	A3	20020911		
EP 1144393	B1	20040211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002521376	T	20020716	JP 2000-561180	19990720 <--
AT 259359	T	20040215	AT 1999-934897	19990720
US 6441012	B1	20020827	US 2001-744331	20010123 <--

PRIORITY APPLN. INFO.:

GB 1998-15971	A	19980723
GB 1998-15973	A	19980723

OTHER SOURCE(S): MARPAT 132:122612

GI



I



II

AB The title compds. [I; A = (un)substituted bicyclic heteroaryl; B = linker group connecting group A to group D and comprising (un)substituted 3 or 4 atom linker where each atom is independently selected from C, O, N and S; C = (un)substituted aryl, mono or bicyclic heteroaryl; D = (un)substituted aryl, heteroaryl; R1 = H, alkyl, alkanoyl, alkoxycarbonyl; R2-R5 = H, alkyl, (un)substituted aryl, etc.; two of R2-R5 can be taken together to form a 3-7 membered ring; R6 = acidic functional group; r, s = 0-1 with the proviso that r and s cannot both be 0], useful for treating multiple sclerosis, rheumatoid arthritis, asthma, coronary artery disease, psoriasis, atherosclerosis, transplant rejection, inflammatory bowel disease, insulin-dependent diabetes and glomerulonephritis, were prepared E.g., a multi-step synthesis of benzoxazole II was given. Compds. I are effective at 0.1-15 mg/kg/day.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1999:784149 CAPLUS Full-text

DOCUMENT NUMBER: 132:36180

TITLE: Macromolecular photoinitiators and their applications

INVENTOR(S): Asakura, Toshikage; Ohwa, Masaki; Yamato, Hitoshi; Tatsumi, Asako

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9962961	A1	19991209	WO 1999-EP3458	19990520 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9943639	A	19991220	AU 1999-43639		19990520	<--
EP 1086145	A1	20010328	EP 1999-926340		19990520	<--
EP 1086145	B1	20040512				
R: CH, DE, FR, GB, IT, LI						
JP 2002517522	T	20020618	JP 2000-552170		19990520	<--
US 6458864	B1	20021001	US 2000-701457		20001127	<--
PRIORITY APPLN. INFO.:			EP 1998-810501	A	19980529	
			WO 1999-EP3458	W	19990520	

OTHER SOURCE(S): MARPAT 132:36180
GI



I

AB The title photoinitiators are prepared by thermal polymerization of a monomer and a photoinitiator containing a chain transfer group. The macrophotoinitiators are polymerized photochem. to give block copolymers. A photoinitiator prepared from I and methacrylic acid was polymerized with styrene using UV irradiation to give a block copolymer.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:392757 CAPLUS Full-text
DOCUMENT NUMBER: 129:68148
ORIGINAL REFERENCE NO.: 129:14150h,14151a
TITLE: α-aminoacetophenones as photoinitiators
INVENTOR(S): Ohwa, Masaki; Yamoto, Hitoshi; Birbaum, Jean-Luc; Nakashima, Hiroko; Matsumoto, Akira; Oka, Hidetaka
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: Ger. Offen., 46 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
DE 19753655	A1	19980610	DE 1997-19753655	19971203	<--
DE 19753655	B4	20080515			
IN 1997DE03201	A	20090313	IN 1997-DE3201	19971107	
TW 452575	B	20010901	TW 1997-86116781	19971108	<--
GB 2320027	A	19980610	GB 1997-23965	19971114	<--
GB 2320027	B	20010509			
SG 73482	A1	20000620	SG 1997-4082	19971118	<--
CH 692422	A5	20020614	CH 1997-2735	19971126	<--
BE 1012647	A5	20010206	BE 1997-953	19971127	<--
AU 9746773	A	19980611	AU 1997-46773	19971128	<--
AU 741581	B2	20011206			
US 6022906	A	20000208	US 1997-982147	19971201	<--

CA 2223376	A1	19980606	CA 1997-2223376	19971203	<--
FR 2758139	A1	19980710	FR 1997-15289	19971204	<--
FR 2758139	B1	20010420			
NL 1007707	A1	19980609	NL 1997-1007707	19971205	<--
NL 1007707	C2	19981027			
CN 1184117	A	19980610	CN 1997-125438	19971205	<--
CN 1134456	C	20040114			
ZA 9710956	A	19980615	ZA 1997-10956	19971205	<--
AT 500120	A1	20051015	AT 1997-2069	19971205	
AT 500120	B1	20070315			
JP 10291969	A	19981104	JP 1997-354199	19971208	<--
BR 9706068	A	20000321	BR 1997-6068	19981203	<--
PRIORITY APPLN. INFO.:			EP 1996-810854 A	19961206	
			DE 1997-19753655 T0	19971203	

OTHER SOURCE(S): MARPAT 129:68148

AB The title compds., of specified structure. are prepared for use as initiators of photopolymn. Adding 120 mL PhCl dropwise to 0.41 mol 2-bromo-1-(4-fluorophenyl)2-methyl-1-propanone in 80 mL MeOH containing 0.45 mol NaOMe at 20° gave 90.8 g crude (4-fluorophenyl)-3,3-dimethyl-2-methoxyoxirane which, after vacuum distillation, was refluxed (0.35 mol) with 200 mL morpholine for 26 h to give 88.1 g 1-(4-fluorophenyl)-2-methyl-2-morpholinyl-1-propanone (I). Adding 80 mmol I in AcNMe2 over 14 h to 0.488 mol 1,3-propanedithiol and 22 g K2CO3 in AcNMe2 at 40° and stirring for 5 h gave 1-[4-[(3-mercaptopropyl)thio]phenyl]-2-methyl-2-morpholino-1-propanone. Use of the products in photopolymn. is exemplified.

L6 ANSWER 30 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:226847 CAPLUS Full-text

DOCUMENT NUMBER: 128:282789

ORIGINAL REFERENCE NO.: 128:55979a,55982a

TITLE: Preparation of N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity

INVENTOR(S): Beard, Richard L.; Teng, Min; Colon, Diana F.; Duong, Tien T.; Chandraratna, Roshantha A.

PATENT ASSIGNEE(S): Allergan, USA

SOURCE: U.S., 21 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5739338	A	19980414	US 1996-744210	19961105	<--
CA 2270893	A1	19980514	CA 1997-2270893	19971029	<--
CA 2270893	C	20081021			
WO 9819999	A1	19980514	WO 1997-US19915	19971029	<--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW					
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
AU 9851011	A	19980529	AU 1998-51011	19971029	<--

AU 729997	B2	20010222			
EP 937045	A1	19990825	EP 1997-913959		19971029 <--
EP 937045	B1	20040428			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2001504458	T	20010403	JP 1998-521637		19971029 <--
AT 265436	T	20040515	AT 1997-913959		19971029
ES 2219760	T3	20041201	ES 1997-913959		19971029
PRIORITY APPLN. INFO.:			US 1996-744210	A	19961105
			WO 1997-US19915	W	19971029

OTHER SOURCE(S): MARPAT 128:282789

GI



I



II

AB The title compds. [I; R1 = H, C1-6 alkyl; R2 = C1-6 alkyl, F, Cl, Br, I; n = 0-3; R3 = C1-6 alkyl, F; X1, X2 = H, C1-6 alkyl; X1X2 = O; R4 = (un)substituted Ph, naphthyl, thienyl, etc.; Z = C.tplbond.C;(CR1:CR1)n (n = 0-5), CONR1; NR1CO; Y = (un)substituted Ph, naphthyl, heteroaryl; A = (CH2)q (q = 0-5), C3-6 alkyl, C3-6 cycloalkyl, etc.; B = H, COOH, CH2OH, etc.] having retinoid, retinoid antagonist or retinoid inverse agonist-like biol. activity, were prepared Thus, reaction of 4,4-dimethyl-1,2,3,4-tetrahydro-N-(4-methylphenyl)-7-ethynylquinoline (preparation described) with Et 4-iodobenzoate in the presence of Et3N, CuI and PdCl2(Ph3P)2 followed by hydrolysis of the resulting Et 4-{2-[4,4-dimethyl-1,2,3,4-tetrahydro-N-(4-methylphenyl)quinolin-7- yl]ethynyl}benzoate with aqueous LiOH in THF/MeOH afforded the title compound II which showed Ki of 13 nM against RARα binding.

REFERENCE COUNT: 117 THERE ARE 117 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1997:361630 CAPLUS Full-text
DOCUMENT NUMBER:	126:330623
ORIGINAL REFERENCE NO.:	126:64259a,64262a
TITLE:	Preparation of 4-anilinopyrido[3,4-d]pyrimidines and analogs as protein tyrosine kinase inhibitors

INVENTOR(S): Cockerill, George Stuart; Guntrip, Stephen Barry; Mckeown, Stephen Carl; Page, Martin John; Smith, Kathryn Jane; Vile, Sadie; Hudson, Alan Thomas; Barraclough, Paul; Franzmann, Karl Witold; et al.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Cockerill, George Stuart; Guntrip, Stephen Barry; Mckeown, Stephen Carl; Page, Martin John; Smith, Kathryn Jane

SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9713771	A1	19970417	WO 1996-EP4399	19961010 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
AU 9672896	A	19970430	AU 1996-72896	19961010 <--
ZA 9608551	A	19970718	ZA 1996-8551	19961010 <--
EP 861253	A1	19980902	EP 1996-934612	19961010 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11513398	T	19991116	JP 1996-514711	19961010 <--
IN 1996DE02215	A	20050311	IN 1996-DE2215	19961010
US 6169091	B1	20010102	US 1998-51324	19980826 <--

PRIORITY APPLN. INFO.:		GB 1995-20845	A 19951011
		GB 1996-14757	A 19960713
		WO 1996-EP4399	W 19961010

OTHER SOURCE(S): MARPAT 126:330623

GI



AB Title compds. [I; R = YZ1ZR4; R2 = H, halo, CF3, alkyl, alkoxy; R4 = cycloalkyl, Ph, thienyl, pyridyl, etc.; R6R7 = atoms to complete a (heteroaryl-substituted) heterocyclic ring; X = N or CH; Y = O, OCH2, SO0-2, (alkyl)imino, etc.; Z = O, CH2, NRb, OCH2, etc.; Rb = H or alkyl; NRbR4 = heterocyclyl; Z1 = (un)substituted phenylene] were prepared Thus, 4,6-dichloropyrido[3,4-d]pyrimidine was aminated by 4-(PhCH2O)C6H4NH2 and th product condensed with 5-tributylstannyl-N-methylimidazole to give title compound II. Data for biol. activity of I were given.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 32 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:205247 CAPLUS Full-text
DOCUMENT NUMBER: 126:205763
ORIGINAL REFERENCE NO.: 126:39656h,39657a,39658a
TITLE: Preparation of organosilicon compounds, and liquid-crystal composition and liquid-crystal display element
INVENTOR(S): Kondo, Tomoyuki; Matsui, Shuichi; Hachiya, Norihisa; Nakagawa, Etsuo
PATENT ASSIGNEE(S): Chisso Corp., Japan
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705144	A1	19970213	WO 1996-JP2103	19960726 <--
W: CN, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CN 1195352	A	19981007	CN 1996-196782	19960726 <--
EP 872484	A1	19981021	EP 1996-925097	19960726 <--
EP 872484	B1	20021002		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL				
AT 225353	T	20021015	AT 1996-925097	19960726 <--
JP 3751640	B2	20060301	JP 1997-507462	19960726
US 5993690	A	19991130	US 1998-409	19980126 <--
PRIORITY APPLN. INFO.:			JP 1995-211211 A	19950727
			WO 1996-JP2103 W	19960726

OTHER SOURCE(S): MARPAT 126:205763
AB Organosilicon compds. represented by the general formula Ra-A-(Z1-A1)m-(Z2-A2)n-(Z3-A3)o-Rb [I; at least one of Ra, Rb, Z1, Z2 and Z3 has an SiH2 group; Ra = H or C1-2 alkyl wherein at least one CH2 group may be substituted by SiH2, O, S, CO, CH:CH, C.tplbond.C, or 1,4-cyclobutylene; Rb = a group of any of the Ra groups, halo or cyano; A, A1, A2 and A3 represent each a bivalent ring group; Z1, Z2 and Z3 represent each independently a covalent bond or (CH2)p wherein at least one CH2 group may be substituted by SiH2, O, S, CO, CH:CH or C.tplbond.C; p represents an integer of 1 to 4; m, n and o represent each independently 0 or 1], which are excellent in the compatibility with other liquid-crystal materials, reduced in viscosity, and improved in threshold voltage, are prepared A liquid crystal composition containing at least one silicon compound I and a liquid crystal display device using said liquid crystal composition are claimed. Thus, 10.0 g 4-bromo-4'-butoxybiphenyl was treated dropwise with BuLi in Et2O at -50°, stirred at -50° for 30 min, warmed to room temperature, stirred for 3 h, and resulting reaction mixture was added dropwise to a solution of 11.6 g propyltrichlorosilane in 10 mL THF at -50°, and stirred at -50° for 30 min and at room temperature for 48 h to give 4.6 g 4-propyldichlorosilyl-4'-butoxybiphenyl. The latter compound (3.0 g) was dissolved in Et2O and reduced by LiAlH4 at room temperature for 10 h to give 7.8% 4-propylsilyl-4'-butoxybiphenyl.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 33 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:186975 CAPLUS Full-text
DOCUMENT NUMBER: 126:212053

ORIGINAL REFERENCE NO.: 126:41007a,41010a
TITLE: Preparation of bis[bi(aryl/heteroaryl)] compounds as inhibitors of leukotriene biosynthesis
INVENTOR(S): Friesen, Richard; Dube, Daniel; Ducharme, Yves; Lepine, Carole; Delorme, Daniel; Hamel, Pierre
PATENT ASSIGNEE(S): Merck Frosst Canada Inc., Can.
SOURCE: Can. Pat. Appl., 80 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2169231	A1	19960816	CA 1996-2169231	19960209 <--
US 5576338	A	19961119	US 1995-388787	19950215 <--
PRIORITY APPLN. INFO.:			US 1995-388787 A	19950215

OTHER SOURCE(S): MARPAT 126:212053
GI



II

AB The title compds. Ar1Ar2-X-Ar3Ar4 [I; Ar1, Ar4 = (un)substituted 5-membered aromatic ring containing one O or S and 0-3 N, 5-membered aromatic ring containing 1-4 N, 6-membered aromatic ring containing 0-3 N; Ar2 = (un)substituted arylene = 6-membered aromatic ring containing 0-3 N; Ar3 = (un)substituted arylene = 10-membered bicyclic aromatic ring containing 0-3 N, 2H-1-benzopyran-2-one, 2H-2-thioxo-1-benzopyran; X = OCH2, CH2O, O, S, S(O), S(O)2], useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents, and also in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques, were prepared Thus, reaction of 3-fluoro-5-(4-pyridyl)phenol with 7-bromomethyl-2-cyano-4-(3-furyl)quinoline in the presence of Cs2CO3 in DMF afforded the title compound II. In general, compds. I are effective at 0.1-10 mg/kg/day.

L6 ANSWER 34 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1997:134915 CAPLUS Full-text
DOCUMENT NUMBER: 126:144107
ORIGINAL REFERENCE NO.: 126:27853a,27856a
TITLE: Preparation of 5-aminoalkyl-2-(2-alkoxyphenyl)pyrroles having affinity for dopamine D3 receptors and their

use in the treatment of psychoses
INVENTOR(S): Watts, Eric Alfred
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Watts, Eric Alfred
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700243	A1	19970103	WO 1996-EP2498	19960607 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 832064	A1	19980401	EP 1996-920811	19960607 <--
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 11507657	T	19990706	JP 1996-502608	19960607 <--

PRIORITY APPLN. INFO.: GB 1995-12129 A 19950615
WO 1996-EP2498 W 19960607
OTHER SOURCE(S): MARPAT 126:144107
GI



I

AB The title compds. [I; R1 = C1-4 alkyl; R3 = (un)substituted Ph, 5- or 6-membered heterocyclic aromatic group; R2, R4, R5 = H, halo, C1-4 alkyl, etc.; Y = 1-(1-piperidinyl)ethyl, N-substituted 2-pyrrolidinyl, 2-piperidinyl, etc.], dopamine D3 antagonists with potential for the treatment of schizophrenia, were prepared and formulated. Thus, treatment of N-acetylpiperidine with POCl3 followed by addition of 2-[(5-ethylsulfonyl-2-methoxy-4-phenyl)phenyl]-1H-pyrrole in ClCH2CH2Cl, and treatment of the reaction mixture with NaBH4 afforded 38% I [R1 = Me; R2, R5 = H; R3 = Ph; R4 = EtSO2; Y = 1-(1-piperidinyl)ethyl] which showed IC50 of 4 nM at the human D3 receptor.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 35 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:724140 CAPLUS Full-text
DOCUMENT NUMBER: 125:343103
ORIGINAL REFERENCE NO.: 125:63853a,63856a
TITLE: Optically active liquid crystal compound containing deuterium atoms for display device
INVENTOR(S): Koizumi, Yasuyuki; Demus, Dietrich; Matsui, Shuichi; Miyazawa, Kazutoshi; Sekiguchi, Yasuko; Nakagawa, Etsuo
PATENT ASSIGNEE(S): Chisso Corp., Japan
SOURCE: Eur. Pat. Appl., 88 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 735015	A2	19961002	EP 1996-300655	19960130 <--
EP 735015	A3	19970611		
R: CH, DE, FR, GB, IT, LI				
JP 08325174	A	19961210	JP 1995-347773	19951214 <--
PRIORITY APPLN. INFO.:			JP 1995-100105 A	19950331

OTHER SOURCE(S): MARPAT 125:343103
GI



I

AB The title compound is represented by the formula I (R1, R2 = H, cyano, halogen, or alkyl or halogenated alkyl with 1-20 C atoms with the proviso that ≥1 methylene group in the alkyl group may be substituted by O, S, CH=CH, C.tplbond.C, CO, CF=CF, CF2, or a cycloalkane or cycloalkene ring with 3-5 C atoms; Z1-3 = a covalent bond or an alkylene group with 1-4 C atoms with the proviso that ≥1 methylene group in the alkylene group may be substituted by O, S, CH=CH, C.tplbond.C, CO, CF=CF, CF2, or a cycloalkane or cycloalkene ring with 3-5 C atoms; m, n = 0 or 1; rings A, B, C, D = a benzene, bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, naphthalene, 1,2,3,4-tetrahydronaphthalene, perhydronaphthalene, fluorene, phenanthrene, 9,10-dihydrophenanthrene, indane, indene, cycloalkane, or cycloalkene ring which may be substituted by O, S, or N atoms) with optically active C atoms bonded to D atoms. With the use of the title compound, it is possible to prepare a liquid crystal composition with controlled pitch and spiral direction without the use of a chiral dopant.

L6 ANSWER 36 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:616620 CAPLUS Full-text
DOCUMENT NUMBER: 125:275529
ORIGINAL REFERENCE NO.: 125:51521a,51524a
TITLE: Process for the stereospecific synthesis of azetidinones
INVENTOR(S): Thiruvengadam, Tiruvettipuram K.; Tann, Chou Hong; Mcallister, Timothy L.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S., 16 pp., Cont.-in-part of U. S. Ser. No. 179,008. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5561227	A	19961001	US 1994-265466	19940623 <--
CA 2114007	A1	19930204	CA 1992-2114007	19920721 <--
CA 2114007	C	20051220		
AU 9223980	A	19930223	AU 1992-23980	19920721 <--
AU 658441	B2	19950413		
ZA 9205487	A	19930331	ZA 1992-5487	19920721 <--
EP 596015	A1	19940511	EP 1992-916790	19920721 <--
EP 596015	B1	19971001		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06508637	T	19940929	JP 1992-502964	19920721 <--
JP 2525125	B2	19960814		
US 5306817	A	19940426	US 1992-962768	19921019 <--
LV 10429	B	19950820	LV 1992-550	19921229 <--
LT 3369	B	19950825	LT 1992-261	19921229 <--
US 6093812	A	20000725	US 1994-179008	19940107 <--
NO 9400221	A	19940121	NO 1994-221	19940121 <--

PRIORITY APPLN. INFO.:

US 1991-734426	B2	19910723
US 1991-734652	B2	19910723
US 1992-962768	A3	19921019
US 1994-179008	A2	19940107
WO 1992-US5972	W	19920721

OTHER SOURCE(S): CASREACT 125:275529; MARPAT 125:275529

GI



I

AB Azetidinone derivs. are prepared stereospecifically by using a chiral oxazolidinone auxiliary. Thus, (R)-(+)-4-benzyl-2-oxazolidinone was acylated with Ph(CH2)4COCl, followed by aldol condensation with 4-MeOC6H4CHO, transamidation with 4-MeOC6H4NH2, and cyclization with EtO2CN:NCO2Et-PBu3 to give the azetidinone I.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 37 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1995:881320 CAPLUS Full-text
DOCUMENT NUMBER:	123:285781
ORIGINAL REFERENCE NO.:	123:51211a,51214a
TITLE:	Preparation of (pyranylbenzyloxy)coumarins and analogs as leukotriene biosynthesis inhibitors
INVENTOR(S):	Fortin, Rejean; Girard, Yves; Grimm, Erich; Hutchinson, John; Scheigetz, John
PATENT ASSIGNEE(S):	Merck Frosst Canada Inc., Can.
SOURCE:	Can. Pat. Appl., 85 pp. CODEN: CPXXEB
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
CA 2125824	A1	19941224	CA 1994-2125824	19940614	<--
CA 2125824	C	20060711			
US 5424320	A	19950613	US 1993-81528	19930623	<--

PRIORITY APPLN. INFO.: US 1993-81528 A 19930623
OTHER SOURCE(S): CASREACT 123:285781; MARPAT 123:285781
GI



AB Title compds. [I; R = heterocyclyl group Q; R1 = H, OH, alkyl(oxy); R2,R4 = H, alkyl; R1R2 = O; R3 = H, (hydroxy)alkyl, alkoxyalkyl; R1R3 = (saturated)(oxa)alkylene; R7 = H, OH, alkyl(oxy), etc.; R9 = H, halo, OH, alkyl(oxy), etc.; R10 = H, alkyl, heteroaryl, etc.; R11,R12 = H, alkyl; R11R12 = bond; X1 = O, SO0-2, CH2; X2 = O, S, CH2, etc.; X3 = O, SO0-2, OCH2, CH2O, etc.; Z = (hetero)arylene; Z1 = CH(R5)m; R5 = H, OH, alkyl(oxy); m = 0 or 1] were prepared as leukotriene biosynthesis inhibitors (no data). Thus, 2,4-(HO)2C6H3COPh was etherified by 3-(4-hydroxytetrahydropyran-4-yl)benzyl bromide (preparation given) and the product cyclocondensed with Ph3P:CH2CO2Me to give title compound II.

L6 ANSWER 38 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1995:14536 CAPLUS Full-text
DOCUMENT NUMBER:	122:72018
ORIGINAL REFERENCE NO.:	122:13491a,13494a
TITLE:	Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
INVENTOR(S):	Girard, Yves; Delorme, Daniel; Fortin, Rejean; Dube, Daniel; Hamel, Pierre; Lepine, Carol; Ducharme, Yves
PATENT ASSIGNEE(S):	Merck Frosst Canada, Inc., Can.
SOURCE:	U.S., 39 pp. Cont.-in-part of U.S. Ser. No. 906,067, abandoned. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 5308852	A	19940503	US 1992-936807	19920827	<--
CA 2099061	A1	19931230	CA 1993-2099061	19930623	<--
CA 2099061	C	20030819			
EP 579304	A1	19940119	EP 1993-201829	19930624	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
ZA 9304623	A	19931222	ZA 1993-4623	19930628	<--
AU 9341569	A	19940106	AU 1993-41569	19930628	<--
WO 9400444	A1	19940106	WO 1993-CA271	19930628	<--
W: BB, BG, BR, BY, CZ, FI, HU, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US					
RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CN 1087907	A	19940615	CN 1993-109518	19930628	<--
JP 06087847	A	19940329	JP 1993-185527	19930629	<--
JP 07116173	B	19951213			
PRIORITY APPLN. INFO.:			US 1992-906067	B2 19920629	
			US 1992-936807	A 19920827	

OTHER SOURCE(S): MARPAT 122:72018
GI



I

AB Compds. I [R1, R5 = H, OH, lower alkyl, lower alkoxy; R2 = H, lower alkyl, or together with R1 forms :O; R3 = H, lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, or R1 and R3 may join to form mono-oxa, monocarbon bridge; R4, R6, R13 = H, lower alkyl; R7 = H, OH, lower alkyl, lower alkoxy, etc.; R8 = H, halo, lower alkyl, OH, lower alkoxy, CF3, CN, COR13; R9 = H, lower alkyl, lower alkoxy, hydroxy lower alkyl, etc.; R10, R11 = H, lower alkyl, lower alkoxy, hydroxy lower alkyl, lower alkoxy, etc.; X1, X2 = O, C(R6)2 (one but not both of X1 or X2 is O); X3 = C(R6)2O, OC(R6)2; Ar1 = arylene-(R8)2 (arylene = phenylene, pyridylene, thiaylene); Ar2 = aryl-(R9)2 (aryl = 5-membered aromatic ring with 1 O or S and 0-3 N, 5-membered aromatic ring with 1-4 N, 6-membered aromatic ring with 0-3 N, 2- or 4-pyranone, etc., with provisos)] are inhibitors of leukotriene biosynthesis. These compds. are useful as antiasthmatic, antiallergic, antiinflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis and allograft rejection, and in preventing the formation of atherosclerotic plaques. Preparation of a large number of I and of intermediates therefor is included.

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 39 OF 39 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:298482 CAPLUS Full-text

DOCUMENT NUMBER: 120:298482
ORIGINAL REFERENCE NO.: 120:52604h,52605a
TITLE: Carbostyril derivatives and salts thereof, anti-arrhythmic agents containing them, and their preparation
INVENTOR(S): Tabusa, Fujio; Nagami, Kazuyoshi; Tsutsui, Hironori
PATENT ASSIGNEE(S): Higuchi, Yoshinari, Japan
SOURCE: Pat. Specif. (Aust.), 148 pp.
CODEN: ALXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 639529	B2	19930729	AU 1991-70939	19910211 <--
AU 9170939	A	19910509		

PRIORITY APPLN. INFO.: AU 1991-70939 19910211
OTHER SOURCE(S): MARPAT 120:298482
GI



I

AB Carbostyrils and dihydro derivs. I [R1 = H, alkyl, alkenyl, alkynyl, phenylalkyl, carboxyalkyl, phenylalkoxyalkyl, amidoalkyl, saturated heterocyclylcarbonylalkyl; R2 = N3, azidocarbonyl, phthalimido, pyrrolidinyl, pyridyl, various (un)substituted NH2 groups, piperidinyl, quinuclidinyl; R3 = alkyl, haloalkyl, alkoxy, OH, halo, CO2H, Ph, phenylalkoxy, alkenyloxy, alkanoylalkoxy, alkylaminocarbonylalkoxy; n = 0, 1, 2; optional 3,4-double bond], some of which are novel and/or prepared, are useful as antiarrhythmics. For example, cyclization of 2-[2-(4-benzyl-1-piperidinyl)acetyl]amino-3-methylbenzaldehyde by NaOEt in refluxing EtOH gave I [R1 = H, R2 = 8-Me, R3 = 3-(4-benzyl-1-piperidinyl); Δ3 present], isolated as the HCl salt. Various I were active at 3-300 μmol doses when tested against elec.-stimulated contractions of isolated feline cardiac muscle samples. Approx. 170 I (free bases and/or salts) are listed with phys. data, and antiarrhythmic test data are given for 27 compds.

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 08:17:15 ON 06 APR 2009